DDInter480 DDInter1544
Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Darifenacin {u} (Compound) resembles {v} (Compound) Fentanyl
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Darifenacin {u} (Compound) binds {v} (Gene) CHRM5
Darifenacin {u} (Compound) upregulates {v} (Gene) MYB
Darifenacin {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Muscarinic Antagonists
Darifenacin {u} (Compound) downregulates {v} (Gene) RNF167
Darifenacin {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Darifenacin {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Darifenacin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clidinium
Darifenacin (Compound) resembles Fentanyl (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Darifenacin (Compound) binds CHRM5 (Gene)
Darifenacin (Compound) upregulates MYB (Gene)
Darifenacin (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class)
Darifenacin (Compound) downregulates RNF167 (Gene)
Darifenacin (Compound) causes Oedema peripheral (Side Effect)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Darifenacin may lead to a major life threatening interaction when taken with Tamoxifen
Darifenacin (Compound) resembles Clidinium (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Clidinium